Results 171 to 180 of about 71,512 (251)

First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary. [PDF]

Life (Basel)
Lakatos KF, Kalmár L, Lahm E, Bíró EG, Fülöp V.   +4 more
europepmc   +1 more source

Role of Radiotherapy in Advanced Stage Hodgkin Lymphoma With Bulky Disease: A Systematic Review and Meta‐Analysis

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background and Purpose: Hodgkin lymphoma (HL) is an uncommon malignancy predominantly affecting young adults. Chemotherapy is the main treatment, with radiotherapy used selectively in early‐stage disease. This meta‐analysis evaluates the impact of adding radiotherapy to bulky disease sites in advanced‐stage HL patients who achieve complete ...
Ahmad Masoud, Louai Alsaloumi, Ahmed Salem, Fanar Alsmarat, Mohammad Alsheikh, Jenan Alfayyoumi, Ftoon Abu Bader, Ranya Alsallal, Lujen Alelaimat, Zaid Daboubi, Rama Alkhatib, Salah Ibrahim, Abdelmomen Hassan   +12 more
wiley   +1 more source

Expression and prognostic impact of CD73 in classical Hodgkin lymphoma. [PDF]

Ann Hematol
Liu B, He C, Liu H, Ma G, Zhang S, Liu Y, Liu C, Li K, Wang Y, Liu Y, Yue M, Liu C, Wang X, Yin S, Li Z.   +14 more
europepmc   +1 more source

T‐Cell Acute Lymphoblastic Leukemia in a Young Patient With Andersen–Tawil Syndrome Successfully and Safely Treated With Intensive Chemotherapy Including Potential Precipitating Drugs: A Case Report After 3.5 Years of Follow‐up

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Andersen–Tawil syndrome (ATS) is a rare, hereditary channelopathy characterized by periodic paralysis, cardiac arrhythmias, and sometimes developmental anomalies. No association with hematologic malignancies has previously been reported. We describe the case of a 27‐year‐old man with genetically confirmed Type 1 ATS who developed T‐cell acute ...
Ramy Rahmé, Paule Moussounda Bamba, Thi Thuy Duong Do, Anthony Behin, Estelle Gandjbakhch, Claude Gardin, Thorsten Braun   +6 more
wiley   +1 more source

Clinical features, central nervous system risk, and therapeutic outcomes in primary sinonasal diffuse large B-cell lymphoma: a retrospective cohort study of 94 patients. [PDF]

Transl Cancer Res
Yao N, Wang C, Niu M, Yang L, Cong J, Ye J, Li X, Yang J, Wei L, Wang L.   +9 more
europepmc   +1 more source

Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Mohammad Shahzaib Qadir, Shereen Farooq, Omer Jamy   +2 more
wiley   +1 more source

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients. [PDF]

Sci Rep
Hecker DJ, Remke MKH, Linxweiler M, Furtwängler R, Akrasu Y, Schöndorf D, Graf N, Krieter D, Oberkircher N, Schick B, Bozzato A, Simon A.   +11 more
europepmc   +1 more source

Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer, Richard Houlston, Martin F. Kaiser   +2 more
wiley   +1 more source

Adult-onset refractory retroperitoneal neuroblastoma with diagnostic and therapeutic challenges: a case report and review of literature. [PDF]

J Med Case Rep
Karna NK, Pokhrel G, Osti A, Neupane N, Pokhrel P, Bhattarai K, Ray R, Khanal S, Sharma R, Dulal S.   +9 more
europepmc   +1 more source